San Diego, USA-based Illumina says that a federal jury in Wilmington, Delaware, found that it had infringed the five patents asserted by Affymetrix and ordered Illumina to pay around $16.7 million in damages to Affymetrix for sales its through the end of 2005.
Jay Flatley, Illumina's chief executive, stated: "we disagree with, and plan to appeal, the present finding of infringement in this law suit, and note that this finding was made without consideration of the validity and enforceability of any of the patents asserted by Affymetrix. That infringement finding is therefore preliminary. With respect to damages, Illumina notes that the jury rejected Affymetrix' request for lost profits, and awarded less than half of the total damages sought by Affymetrix in this trial."
He added: "the case will now proceed to the next phases during which we will have the opportunity to demonstrate that the jury's infringement verdict should not stand because these claims are invalid and unenforceable. In the meantime, we will continue to sell the products that are the subject of this suit and no damages will be payable to Affymetrix until all appropriate appeals have been taken."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze